Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy

Yuanzi Liang and Daowei Li*

Abstract

Background: This study was performed to systematically evaluate the accuracy of magnetic resonance elastography (MRE) in staging of liver fibrosis in non-alcoholic fatty liver disease (NAFLD).

Methods: PUBMED, EMBASE, Web of Science, CNKI, Cochrane Library database were searched from January 2008 to December 2018 for studies related to MRE in the diagnosis of NAFLD liver fibrosis. The quality of the included literature was assessed by Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. The pooled sensitivity, the pooled specificity, and area under the receiver operating characteristic curve (AUROC) value was performed by STATA 14.0 software.

Results: A total of 12 studies were included, involving 910 patients. The pooled sensitivity and specificity of each group were 0.77 (95%CI 0.69–0.83) and 0.90 (95%CI 0.83–0.94) for F ≥ 1 (mild liver fibrosis), 0.87 (95%CI 0.74–0.94) and 0.86 (95%CI 0.71–0.94) for F ≥ 2 (significant liver fibrosis), 0.89 (95%CI 0.81–0.94) and 0.84 (95%CI 0.63–0.94) for F ≥ 3 (severe liver fibrosis), 0.94 (95%CI 0.85–0.98) and 0.75 (95%CI 0.35–0.94) for F ≥ 4 (early cirrhosis), respectively. The area under the summary receiver operating characteristic (SROC) curve was 0.89, 0.93, 0.93, and 0.95, respectively.

Conclusions: MRE has high accuracy in the diagnosis of hepatic fibrosis staging in patients with NAFLD.

Keywords: Magnetic resonance elastography, Non-alcoholic fatty liver disease, Liver fibrosis, Systematic review

Key points

1. A total of 910 patients with 12 high-quality studies were systematically analyzed to investigate the accuracy of MRE in staging diagnosis of NAFLD liver fibrosis.
2. The pooled values of sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR) and diagnostic odds ratio (DOR) were analyzed.
3. The pooled sensitivity and specificity of four stages of liver fibrosis were shown that MRE has high accuracy in the diagnosis of hepatic fibrosis staging in patients with NAFLD.

Background

Nonalcoholic fatty liver disease (NAFLD), a worldwide epidemic, is a chronic liver disease associated with cirrhosis, which affects 25% of adults. NAFLD is correlated with components of the metabolic syndrome, such as...
obesity, hypertriglyceridemia, and type 2 diabetes mellitus [1]. NAFLD is classified into simple fatty liver (SFL), nonalcoholic fatty hepatitis (NASH) and NAFLD-related cirrhosis, and NASH is a progressive form that may lead to cirrhosis or hepatocellular carcinoma (HCC) [2, 3]. Due to that staging of fibrosis could indicate disease progression and prognosis in patients with NAFLD, and it is a critical predictors of cirrhosis, hepatocellular carcinoma, and death [4, 5]. Hence, it is critically important for accurate objective tests to detect liver fibrosis in patients with NAFLD.

Biopsy is still considered the gold standard for the diagnosis of liver fibrosis stage in NAFLD [4], but invasive examination may cause sampling error and intra- and inter-observer variability, and may be complicated by morbidity and even death [6]. Therefore, it is needed to develop noninvasive tests that can detect advanced fibrosis in NAFLD patients, but there still remains no noninvasive test approved to diagnose fibrosis in NAFLD patients.

Currently, Noninvasive markers such as Cytokeratin-18, NAFLD fibrosis score, and Enhanced Liver Fibrosis (ELFTM) Test have been proposed for evaluating liver fibrosis, but may not be sufficiently accurate in routine clinical use. Ultrasound-based imaging tests, such as transient elastography (FibroScan) and acoustic radiation force impulse imaging (ARFI) elastography [7] have high (21–50%) failure rates in obese patients [8], and are evaluated only a limited portion of the liver, and findings may be influenced by necroinflammatory activity [7].

Magnetic resonance elastography (MRE), a magnetic resonance-based imaging technique, could utilize shear waves to characterize liver fibrosis. MRE has made significant progress as a non-invasive test for staging liver fibrosis in NAFLD due to its high accuracy in the evaluation of liver fibrosis and also due to the possibility of evaluating a large area of the parenchyma with the option of choosing the region of interest [9]. Although several recent studies have reported a high diagnostic accuracy of MRE in patients with NAFLD [3, 10–20], but those studies had a limited sample size. In this study, we searched all related studies, and performed a systematic review to systematically evaluate the accuracy of MRE in the diagnosis of liver fibrosis in patients with NAFLD.

**Methods**

**Literature search strategy**

PubMed, Web of Science, CNKI, Embase and Cochrane library database were searched for related literatures in Chinese or English regarding the diagnosis and staging liver fibrosis of NAFLD by MRE. The publication time was from January 2008 to December 2018. The retrieval strategy was (“NAFLD” OR “nonalcoholic fatty liver disease) AND (“liver fibrosis” OR “hepatic fibrosis”) AND (“MRE” OR “MR elastography” OR “magnetic resonance elastography”). In order to perform comprehensive search, the reference lists of the eligible literatures were also searched.

**Inclusion and exclusion criteria**

**Inclusion criteria**

1. NAFLD Patient is older than 18 years old;
2. Studies evaluated the diagnostic performance of MRE, if the study includes other diagnostic test, the corresponding data will still be included in the study;
3. Studies used biopsy as the gold standard.
4. If the study population contained NAFLD and other chronic liver disease, the data of NAFLD is separately extracted;
5. Literatures published from January 2008 to December 2018;
6. True positives, false positives, false negatives and true negatives can be directly or indirectly extracted from the literature to construct a 2 × 2 table.

**Exclusion criteria**

1. Reviews, conferences, case reports, animal experiments and technical literature, etc.;
2. The original data is incomplete to construct the four-grid table;
3. Repeated publication.

**Data extraction**

Two researchers independently screened the literature and extracted the information according to the established inclusion and exclusion criteria, and cross-checked. If there is any inconsistency, it will be resolved through negotiation. The extracted information mainly includes: the first author, publication year, country, study type, the interval between gold standard and MRE examination, patient information (age, BMI, gender), and four-grid data true positive (TP), false positive (FP), false negative (FN), and true negative (TN).

**Assessment of methodological quality**

The quality of the included literature was assessed independently by 2 researchers, and differences were resolved through discussion. Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was introduced to assess the quality of the included studies. The software Review Manager (version 5.3) was used to present the result of assessment. Each item included in the studies in QUADAS-2 tool was evaluated as yes, no or unclear [21, 22]. The Metavir liver fibrosis staging...
evaluation system was used. The system was consistent with the liver fibrosis stage of Batts-Ludwing and Scheuer evaluation system, and was divided into five stages of F0, F1, F2, F3 and F4, among which F0 was non-fibrotic. F ≥ 1 was mild liver fibrosis. F ≥ 2 was significant liver fibrosis. F ≥ 3 was severe liver fibrosis. F ≥ 4 was early cirrhosis.

**Statistical analysis**

According to the required information, data extraction form was created to calculate relevant indicators, and the data was processed by STATA (version 14.0).

**Assessment of heterogeneity and publication bias**

The Q test was used to evaluate the heterogeneity of the included literatures, and the degree of heterogeneity was determined according to the $I^2$ value. If $I^2 \leq 25\%$: less heterogeneity, 25% < $I^2 \leq 50\%$: moderate heterogeneity, $I^2 \geq 50\%$: greater heterogeneity. When the heterogeneity is large, the bivariate mixed effect model should be further adopted. Deeks’ funnel plot was used to detect publication bias when detecting publication bias, and $P \leq 0.01$ indicated that the publication bias was more significant.

**Summery statistics**

By processing the original data of the included studies, true positive, false positive, false negative and true negative were extracted. Systematic review was performed using STATA 14.0 software for F ≥ 1, F ≥ 2, F ≥ 3, and F ≥ 4 separately in the included literatures, the pooled sensitivity, the pooled specificity, the pooled positive likelihood ratio, the pooled negative likelihood ratio and the pooled diagnostic ratio were calculated. The forest graph and the hierarchical summary receive operating characteristic (HSROC) curve were drawn, and the area under the curve (AUC) was calculated to obtain the AUROC value and its confidence interval. $P < 0.05$ indicates statistical significance.

**Meta regression and subgroup analysis**

If there is a high heterogeneity in the included studies, the single independent regression of the continuous independent variables is performed by STATA 14.0 software, and the sub-combinations of each independent variable are calculated and the results obtained.

**Sensitivity analysis**

In order to observe the stability and heterogeneity of the results of the summery statistics, each included literature was excluded for pooled analysis, and the summery statistics were performed on each group. The results of the summery statistics, $I^2$ and those obtained before the exclusion were compared to observe the results.

**Results**

**Literature screening results and basic characteristics**

A total of 642 related studies were preliminarily obtained through the search, and 12 studies [3, 10–20] were finally included for pooled analysis after reading abstracts and full-text screening. A total of 910 patients were included. Of the 12 included articles, 10 [3, 10–14, 17–20] were prospective studies and 2 [15, 16] were retrospective studies. All the included literatures could extract the data of four grids. The study screening process and results are shown in Fig. 1. The basic characteristics of the patients included in the studies are shown in Table 1. The quality evaluation of the included studies is shown in Table 2.

**Pooled analysis results**

**Assessment of heterogeneity and publication bias**

Heterogeneity analysis of F ≥ 1 (mild liver fibrosis), F ≥ 2 (significant liver fibrosis), F ≥ 3 (severe liver fibrosis), and F ≥ 4 (early cirrhosis) groups by Q test. For the sensitivity heterogeneity analysis, the $I^2$ values were 77.35, 84.83, 77.40, and 92.49%, respectively. The specific heterogeneity analysis showed $I^2$ values of 77.78, 90.66, 94.85, and 96.60%, respectively (see Fig. 2 for details). $I^2$ values are greater than 50% suggesting that each group of studies has high heterogeneity and $P < 0.01$, suggesting that the heterogeneity is statistically significant, and a bivariate mixed-effects model is needed for statistical consolidation.

The results of Deeks’ funnel plot for F ≥ 1, F ≥ 2, F ≥ 3 and F ≥ 4 groups were shown in Fig. 3. The funnel plot of each group was relatively symmetrical, with $P$ values of 0.99, 0.53, 0.72 and 0.45, respectively, showing no statistical significance ($P > 0.01$), indicating that there was no significant publication bias in each group.

**Summery statistics**

By combining the diagnostic indicators of liver fibrosis, the pooled values of sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR) and diagnostic odds ratio (DOR) were obtained, and the forest graph and HSROC curve were drawn to calculate the AUROC of each group. The forest graph showed that the pooled sensitivity and specificity of each group were 0.77 (95%CI 0.69–0.83) and 0.90 (95%CI 0.83–0.94) respectively, for F ≥ 1; 0.87 (95%CI 0.74–0.94) and 0.86 (95%CI 0.71–0.94) for F ≥ 2; 0.89 (95%CI 0.81–0.94) and 0.84 (95%CI 0.63–0.94) for F ≥ 3; 0.94 (95%CI 0.85–0.98) and 0.75 (95%CI 0.35–0.94) for F ≥ 4, respectively. The area under the SROC curve were 0.89, 0.93, 0.93, and 0.95, respectively. Other details were shown in Table 3. The HSROC curves of the four groups were shown in Fig. 4.
Meta regression and subgroup analysis

In view of the high heterogeneity of the included studies, this paper conducted meta-regression and subgroup analysis. The independent variables of study type (whether prospective or not), equipment field strength (1.5 T or 3.0 T), and the integrity of basic information of subjects (gender, BMI, age) may be the factors leading to high heterogeneity, as shown in Fig. 5.

F ≥ 1 group: The independent variable type (prodesign) and equipment field (scanner) were significant for the heterogeneity of the pooled sensitivity ($P < 0.05$). The independent variables were not statistically significant for the pooled specificity.

F ≥ 2 group: The independent variables had no statistical significance for the heterogeneity of the pooled sensitivity and specificity.

F ≥ 3 group: The independent variables had no statistical significance for the heterogeneity of the pooled sensitivity and specificity.

F ≥ 4 group: The independent device field strength (scanner) was significant for the heterogeneity of the pooled specificity ($P < 0.05$). The independent variables were not statistically significant for the pooled sensitivity.

Sensitivity analysis

By separately excluding the results obtained after the inclusion of the study, there were two studies that reduced the heterogeneity of the combined statistic obtained after exclusion. The $I^2$ value obtained by the specific heterogeneity analysis was reduced when Loomba 2014 alone was excluded, and the $I^2$ value obtained for the sensitivity heterogeneity analysis was reduced when...
| First author | Year | Study design | Country | Subject | Age (y) | BMI (kg/m²) | Field strength | Interval | Scoring system | Comparison |
|--------------|------|--------------|---------|---------|---------|-------------|----------------|----------|----------------|------------|
| Loomba      | 2016 | prospective  | US      | 100     | 36.6–63.8 | 27.1–37.1   | 3 T            | 46d      | NASH-CRN       | 3D-MRE vs 2D-MRE |
| Cui         | 2016 | prospective  | US      | 125     | 33.5–64.3 | 24.7–38.7   | 3 T            | 46.5d    | NASH-CRN       | MRE vs ARFI  |
| Loomba      | 2014 | prospective  | US      | 117     | 36.7–63.5 | 27.4–37.4   | 3 T            | 45d      | NASH-CRN       | –          |
| Costa-Silva | 2017 | prospective  | Brazil  | 49      | 41.3–66.3 | 273–37.1    | 1.5 T          | 0.3–7.1 m | NASH-CRN       | –          |
| Cui         | 2015 | prospective  | US      | 102     | 37.3–65.3 | 262–37.2    | 3 T            | 90d      | NASH-CRN       | MRE vs eight CPRs |
| Park        | 2017 | prospective  | US      | 104     | 36.2–65.4 | 252–35.6    | 3 T            | 42d      | NASH-CRN       | MRE vs TE   |
| Chen        | 2011 | retrospective | US      | 58      | 25–78     | 212–50.6    | 1.5 T          | 90d      | brunt & kleiner | –          |
| Imajo       | 2016 | retrospective | Japan   | 142     | 42.9–72.1 | 2347–32.73  | 3 T            | <6 m     | brunt & kleiner | MRE vs TE   |
| Wang        | 2011 | prospective  | US      | 5       | 20–74     |             | 1.5 T          | ,1y      | METAVIR        | MRE vs DWI  |
| Godfrey     | 2012 | prospective  | UK      | 8       | 37.5–60.5 |             | 1.5 T          |          | Ishak's score  | MRE vs 31P MR spectroscopy |
| Chen        | 2017 | prospective  | France  | 92      | 45.4–51.75| 38.7–41.8   | 1.5 T          |          | METAVIR        | MRE vs VCTE |
| Huwart      | 2008 | prospective  | France  | 8       | 41–67     | 31–346      | 1.5 T          | 2d       | METAVIR        | MRE vs ultrasound elastography vs APRI |
Chen 2017 alone was excluded. The $I^2$ obtained after two separate exclusions of the literature was still greater than 50%, but the degree of decline was greater than 10%, indicating that partial inclusion of the literature may be a source of heterogeneity.

**Discussion**

In this systematic review, we performed pooled analysis of diagnostic performance of MRE in 12 studies with 910 patients with NAFLD. Regarding the overall diagnostic accuracy of MRE in patients with NAFLD, we...
found that the pooled sensitivities of MRE for diagnosis of liver fibrosis stage F ≥ 1, F ≥ 2, F ≥ 3, F ≥ 4 were 0.77, 0.87, 0.89, and 0.94 respectively, and the pooled specificities were 0.90, 0.86, 0.84, and 0.75, respectively. The area under the SROC curve was 0.89, 0.93, 0.93, and 0.95, among which MRE has the highest accuracy in F4 stage. Due to NAFLED-associated fibrosis is a strong predictor of mortality, cirrhosis, and hepatocellular carcinoma in patients, it is possible to further develop effective clinical treatment by measuring liver elasticity and staging of liver fibrosis in patients with MRE. And the pooled AUROC of stage F ≥ 2, F ≥ 3 and F ≥ 4 was greater than 90%, suggesting excellent discriminative ability for detection of liver fibrosis stage. The optimal threshold values of F ≥ 1, F ≥ 2, F ≥ 3, and F ≥ 4 were different (F ≥ 1 group: 1.77–5.02Kpa, F ≥ 2 group: 2.38–5.37Kpa, F ≥ 3 group: 2.43–5.97Kpa, F ≥ 4 group: 2.74–6.7Kpa), and thus this study couldn’t determine the optimal threshold of fibrosis stage. The possible reasons are as follows: different study designs (10 prospective studies, 2 retrospective studies); different pathological interval time; different MRE technology, parameter setting (6 1.5 T MR, 6 3.0 T MR) and operator’s technical experience; when post-processing is used to obtain an elastic diagram, the region of interest needs to be manually drawn.

In a systematic review by Singh et al. that included 9 studies reporting on 232 patients [5], the pooled AUROC for MRE diagnosis of NAFLD liver fibrosis stage (F ≥ 1, F ≥ 2, F ≥ 3, F ≥ 4) was 0.86, 0.87, 0.90, and 0.91 respectively, and the values of each group are lower than that in our study. The possible reason may arise from 1) we included more included studies in this study; 2) the bivariate mixed effect model was adopted; 3) as a systematic review, the study of Singh et al. is more like a data-sorted analysis without
relevant heterogeneity analysis and publication bias analysis. In the meta-analysis by Xiao et al. [23], they compared the performance of different noninvasive methods for diagnosing liver fibrosis including APRI, FIB-4, BARD score, NAFLD fibrosis score, FibroScan, shear wave elastography (SWE) and MRE in NAFLD, and found that MRE and SWE may have the highest diagnostic accuracy for staging fibrosis in NAFLD patients (the summary AUROC values was 0.96 and 0.95), which accordingly indicated the high accuracy of MRE diagnosis of NAFLD liver fibrosis. However, the study by Xiao et al. is a meta-analysis of multiple examinations applied to NAFLD, the number of relevant studies is relatively small compared with our study, so the specific analysis of MRE is not detailed enough, and the analysis method is less, so the AUC value is lower than this study. In our study, we performed more deep analysis on diagnostic accuracy of

![Image](64x328 to 532x696)

**Fig. 3** Deeks’ funnel plot indicating the publication bias of the included studies. a: Deeks’ funnel plot for fibrosis stage $F \geq 1$; b: Deeks’ funnel plot for fibrosis stage $F \geq 2$; c: Deeks’ funnel plot for fibrosis stage $F \geq 3$; d: Deeks’ funnel plot for fibrosis stage $F \geq 4$

| Stage | Sensitivity (95%CI) | Specificity (95%CI) | Positive LR (95%CI) | Negative LR (95%CI) | DOR (95%CI) | AUROC (95%CI) | $Q$ test, $I^2$ value | $P$ value |
|-------|---------------------|---------------------|---------------------|---------------------|-------------|--------------|-------------------|----------|
| $F \geq 1$ | 0.77(0.69–0.83) | 0.90(0.83–0.94) | 7.5(4.4–12.7) | 0.26(0.20–0.35) | 29(15–53) | 0.89(0.86–0.92) | 77.35% | 77.78% | 0.99 |
| $F \geq 2$ | 0.87(0.74–0.94) | 0.86(0.71–0.94) | 6.2(3.0–12.6) | 0.15(0.08–0.29) | 41(21–81) | 0.93(0.90–0.95) | 84.83% | 90.66% | 0.53 |
| $F \geq 3$ | 0.89(0.81–0.94) | 0.84(0.63–0.94) | 5.6(2.2–14.2) | 0.13(0.09–0.21) | 42(17–100) | 0.93(0.90–0.95) | 77.40% | 94.85% | 0.72 |
| $F \geq 4$ | 0.94(0.85–0.98) | 0.75(0.35–0.94) | 3.8(1.1–13.1) | 0.08(0.04–0.16) | 50(16–152) | 0.95(0.93–0.97) | 92.49% | 96.60% | 0.45 |

LR Likelihood ratio, DOR Diagnostic odds ratio, AUROC Area under the receiver operating characteristic
the MRE in liver fibrosis stage of NAFLD, further conducted meta regression, subgroup analysis to find sources of heterogeneity, and sensitivity analysis to assess the influence of each study on the overall result. It was proved by many studies that liver stiffness is positively correlated with the severity of liver fibrosis. Elastography is a dynamic imaging technique for measuring the mechanical properties of tissues, which can detect the tissue elasticity (stiffness) [24]. This feature prompts the obvious advantages MRE in the diagnosis of liver fibrosis stage of NAFLD [2, 4]. Georges et al. concluded that hepatocyte swelling and stromal edema (ballooning) caused by inflammation would lead to increased liver stiffness, while
Fig. 5 (See legend on next page.)
Ichikawa et al. observed that hepatitis activity grade may also influence liver stiffness measured using MRE [25, 26]. Therefore, large-scale prospective studies are still needed to investigate the effect of inflammation on the liver hardness measured by MRE. The diagnostic performance is various based on the different technique or machine for MR evaluation. Wagner et al. indicated that the failure rate of overall examination in NAFLD patients was about 7.7%, of which the failure rate of liver MRE was only 3.5% at 3.0 T, while the failure rate was 15.3% at 1.5 T [27]. Loomba et al. performed a prospective study included 100 patients with NAFLD to assess the accuracy of 2D-MRE at 60 Hz, 3D-MRE at 40 Hz and 60 Hz in diagnosing advanced fibrosis [10]. They found that at a threshold of 2.43 kPa, 3D-MRE at 40 Hz had sensitivity 1.0 and specificity 0.94 for diagnosing advanced fibrosis, and concluded that 3D MRE at 40 Hz has the highest diagnostic accuracy in diagnosing NAFLD advanced fibrosis [10]. Compared to 2D-MRE, 3D-MRE allows for improved assessment of spatial patterns of hepatic fibrosis and focal lesions [10]. Salomone et al. suggest that NAFLD fibrosis score can be considered an accurate tool for the stratification of the risk of death in NAFLD patients [28]. Although the diagnostic accuracy of MRE is high as showed by results, it would be important in the future studies to assess the predictive value of MRE for mortality, the “real” outcome for patients with NAFLD.

Due to the high heterogeneity of the included studies, the bivariate mixed effect model was adopted to perform pooled analysis of diagnostic indicators of each group. The sources of heterogeneity were analyzed through sensitivity analysis, meta regression and subgroup analysis and we conclude that the heterogeneity might be related to variety in designs or quality of the included studies, study population and difference in field strength and parameters of MRE equipment. This systematic review has certain limitations: (1) 3 included studies contained other chronic liver diseases, and the amount of NAFLD cases was relatively small relatively to other included studies, and the data may have confound bias, (2) We only retrieves the study in English database, but didn’t search the study published in other languages, which may have information bias, (3) Fibrosis staging errors often occur in clinical diagnosis, so there is the possibility of information bias [29].

Conclusions
In conclusion, MRE has the advantages of low failure rate, high repeatability, and facilitating biopsy procedures, which can be performed in all subjects without MRI contraindications [30]. At the present, MRE has gradually developed from the scientific research to clinical application, and this systematic review displayed that MRE has a high accuracy in diagnosing the stage of NAFLD liver fibrosis. In the future, the MRE technology should be further optimized to achieve more accurate staging of liver fibrosis in patients with NAFLD, and to provide imaging basis for treatment options and disease prognosis.

Abbreviations
MRE: Magnetic resonance elastography; NAFLD: Non-alcoholic fatty liver disease; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies; AUROC: Area under the receiver operating characteristic curve; SROC: Summary receiver operating characteristic; +LR: Positive likelihood ratio; -LR: Negative likelihood ratio; DOR: Diagnostic odds ratio; SFL: Simple fatty liver; NASH: Nonalcoholic fatty hepatitis; HCC: Hepatocellular carcinoma; ELF: Enhanced Liver Fibrosis; ARFI: Acoustic radiation force impulse imaging; BMI: Body Mass Index; TP: True positive; FP: False positive; FN: False negative; TN: True negative; HSROC: Hierarchical summary receive operating characteristic; AUC: Area under the curve; SWE: Shear wave elastography

Acknowledgements
Many thanks to Pro. Daowei Li of The People’s Hospital of Liaoning Province for his help on determining topic and writing paper, which brings benefits to the improvement of my research and innovation capabilities.

PRISMA guidelines
Not applicable.

Authors’ contributions
DL takes responsibility for the integrity of the work as a whole, from inception to published article, YZ performed the research, collected and analysed the data, completed the manuscript. All authors read and approved the final manuscript.

Funding
This study has received funding by the Natural Science Foundation of Liaoning Province (General Projects) (20170561) and the Natural Science Foundation of Liaoning Province (the Doctoral Scientific Research Foundation of Liaoning Province) (1552530224468). The applicant of these two funds is Daowei Li, who has made a significant contribution to the idea of this article. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Received: 15 January 2020 Accepted: 24 March 2020
Published online: 06 April 2020

References
1. Williams CD, Stengel J, Asikie M, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasonar and liver biopsy: a prospective study. Gastroenterology. 2010;140:124.

2. Stefan N, Haring HU, Cusi K. Non-alcoholic liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–24.

3. Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014;60(6):1920–8.

4. Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17(6):e630–e638.

5. Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016;26(5):1431–40.

6. Dulal PS, Sirlin CB, Loomba R, MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2015;63(S5):1006–16.

7. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1346.

8. Castéra L, Foucher J, Bernard PH, Carvalho F, Allak D, Merrouche W, et al. Lédiheng Vd: pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2013;53(5).

9. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehmam RL, Ying W. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR Elastography. Radiology. 2013;360(S5):480.

10. Loomba R, Cui J, Wolfson T, Haufe W, Hooker J, Szeverenyi N, et al. Novel 3D magnetic resonance Elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol. 2016;111(7):986–94.

11. Jeffrey C, Elhamy H, Carolyn H, William H, Jonathan H, Andre MP, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. J Hepatol (Baltimore, Md). 2016;63(2).

12. Luciana CS, Maitinho FS, Soares LA, Teixeira VP, FTCD A. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. %J. Eur J Radiol. 2018;98:1.

13. Cui J, Ang B, Haufe W, Hernandez C, Verna EC, Sirlin CB, et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther. 2015;41(2):1271–80.

14. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance Elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598–607.e592.

15. Chen JT, Yin M, Glaser KJ, Sanderson SO, Ehmam RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011;259:749.

16. Kento I, Takami K, Yasushi H, Wataru T, Yuji O, Hiroshi H, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with non-alcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150:3.

17. Wang Y, Ganger DR, Levitsky J, Sternick LA, McCarthy RJ, Chen ZE, et al. Assessment of chronic hepatitis and cirrhosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol. 2011;196(3):553–61.

18. Godfrey EM, Patterson AJ, Priest AN, Davies SE, Joubert I, Krishnan AS, et al. A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis. Eur Radiol. 2012;22(12):2790–7.

19. Chen J, Yin M, Talwalkar JA, Cutler J, Glaser KJ, Smyrk TC, et al. Diagnostic performance of MR Elastography and vibration-controlled transient Elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology. 2017;283(2):418–28.

20. Huwart L, Sempoux C, Vicaut E, Salameh N, Annert L, Danse E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32–40.

21. Whiting PF, Rujees AH, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. Group Q-QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):S29–36.

22. Wu L, Zhang Y, Zeng X. The QUADAS-2 tool for the quality assessment of diagnostic accuracy study: an introduction. J Hum Univ Med. 2013;32(3):201–8.

23. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486.

24. Hallinan JTD, Alsaf HS, Wee A, Venkatesh SK. Magnetic resonance Elastography of liver: influence of intravenous gadolinium injection on measured liver stiffness. Abdom Imaging. 2015;40(4):785–8.

25. Georges PC, Hui JJ, Gombos Z, McCormick ME, Wang AY, Uemura M, et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol. 2007;293(6):G1147–54.

26. Ichikawa S, Motosugi U, Nakazawa T, Morisaka H, Sano K, Ichikawa T, et al. Hepatitis activity should be considered a confounder of liver stiffness measured with MR Elastography. J Magn Reson Imaging. 2015;41(5):1203–8.

27. Wagner M, Czerewa-Solano R, Lo G, Eises S, Liao J, Besa C, et al. Technical failure of MR Elastography: Examinations of the Liver: experience from a large single-center study. Radiology. 2017;284(2):401–12.

28. Salomone F, Micoc A,Godos G. Simple scores of fibrosis and mortality in patients with NAFLD: a systematic review with meta-analysis. J Clin Med. 2018;7(8).

29. Avegail F, Asrani SK. Editorial: magnetic resonance Elastography and non-alcoholic fatty liver disease: time for an upgrade? Am J Gastroenterol. 2016;111:7.

30. Etchell E, Jugé L, Hatt A, Sinkus R, Bilston LE. Liver stiffness values are lower in morbid obesity. Radiology. 2017;283(2):418–28.

31. Varela P, Castaño C, Estruch R, Martínez-Palomino O, Plà C, Martínez P, et al. A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis. Eur Radiol. 2012;22(12):e789–96.

32. Chen J, Yin M, Talwalkar JA, Cutler J, Glaser KJ, Smyrk TC, et al. Diagnostic performance of MR Elastography and vibration-controlled transient Elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology. 2017;283(2):418–28.

33. Huwart L, Sempoux C, Vicaut E, Salameh N, Annert L, Danse E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32–40.

34. Whiting PF, Rujees AH, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. Group Q-QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):S29–36.

35. Wu L, Zhang Y, Zeng X. The QUADAS-2 tool for the quality assessment of diagnostic accuracy study: an introduction. J Hum Univ Med. 2013;32(3):201–8.

36. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.